OVIT (OncoVista Innovative Therapies) EV-to-EBITDA: -0.00 (As of Jul. 12, 2026)


What is OncoVista Innovative Therapies EV-to-EBITDA?

OncoVista Innovative Therapies OVIT EV-to-EBITDA is -0.00 as of Jul. 12, 2026.

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OncoVista Innovative Therapies's enterprise value is $0.00 Mil. OncoVista Innovative Therapies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 was $-3.26 Mil. Therefore, OncoVista Innovative Therapies's EV-to-EBITDA for today is -0.00.

The historical rank and industry rank for OncoVista Innovative Therapies's EV-to-EBITDA or its related term are showing as below:

OVIT's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 13.14
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-07-12), OncoVista Innovative Therapies's stock price is $0.0001. OncoVista Innovative Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.140. Therefore, OncoVista Innovative Therapies's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

OncoVista Innovative Therapies  (OTCPK:OVIT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

OncoVista Innovative Therapies's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.140
=At Loss

OncoVista Innovative Therapies's share price for today is $0.0001.
OncoVista Innovative Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.140.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

OncoVista Innovative Therapies EV-to-EBITDA Related Terms

OncoVista Innovative Therapies EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies EV-to-EBITDA Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.51 -2.51 -1.42 -0.68 -0.60

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -0.60 -4.05 -7.62 -3.17

OVIT vs RSPI, HSTC, CAPS: EV-to-EBITDA Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's EV-to-EBITDA falls into.


OncoVista Innovative Therapies EV-to-EBITDA Calculation

OncoVista Innovative Therapies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.002/-3.255
=-0.00

OncoVista Innovative Therapies's current Enterprise Value is $0.00 Mil.
OncoVista Innovative Therapies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBITDA →
What does a EV-to-EBITDA of -0.00 mean?
OncoVista Innovative Therapies (OVIT) has a EV-to-EBITDA of -0.00 as of Jul. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OncoVista Innovative Therapies.
Is OncoVista Innovative Therapies' EV-to-EBITDA too high?
OncoVista Innovative Therapies' current EV-to-EBITDA is -0.00.
How does OncoVista Innovative Therapies' EV-to-EBITDA compare to RSPI and HSTC?
OncoVista Innovative Therapies' EV-to-EBITDA of -0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.14, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OncoVista Innovative Therapies. For the Biotechnology industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoVista Innovative Therapies's current EV-to-EBITDA is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current EV-to-EBITDA of -0.00. The current EV-to-EBITDA is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current EV-to-EBITDA is -0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.